Nifedipine and telmisartan for the treatment of hypertension: The TALENT study

Research output: Contribution to journalArticle

Abstract

A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of atherosclerosis in hypertensive subjects and to significantly decrease cardiovascular risk in diabetic patients. Telmisartan is highly selective for the angiotensin receptor 1, it gives a greater improvement in glycemic and lipid control compared with irbesartan, and it proved its superiority in improving insulin sensitivity compared with eprosartan. The TALENT study was aimed to determine whether combining low-dose nifedipine GITS at and telmisartan reduced ambulatory and clinic blood pressure more than the two components in monotherapy in hypertensive patients at high cardiovascular risk. The study shows that combination treatment with nifedipine GITS and telmisartan provides a greater and earlier blood pressure reduction than the combination components in monotherapy.

Original languageEnglish
Pages (from-to)1499-1503
Number of pages5
JournalExpert Review of Cardiovascular Therapy
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Nifedipine
irbesartan
Hypertension
Blood Pressure
Angiotensin Receptors
Calcium Channel Blockers
Drug Combinations
Insulin Resistance
Atherosclerosis
Therapeutics
Lipids
telmisartan

Keywords

  • adverse events
  • blood pressure
  • combination treatment
  • nifedipine
  • telmisartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

@article{19374bb198654931a0b8b9445f15f3f0,
title = "Nifedipine and telmisartan for the treatment of hypertension: The TALENT study",
abstract = "A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of atherosclerosis in hypertensive subjects and to significantly decrease cardiovascular risk in diabetic patients. Telmisartan is highly selective for the angiotensin receptor 1, it gives a greater improvement in glycemic and lipid control compared with irbesartan, and it proved its superiority in improving insulin sensitivity compared with eprosartan. The TALENT study was aimed to determine whether combining low-dose nifedipine GITS at and telmisartan reduced ambulatory and clinic blood pressure more than the two components in monotherapy in hypertensive patients at high cardiovascular risk. The study shows that combination treatment with nifedipine GITS and telmisartan provides a greater and earlier blood pressure reduction than the combination components in monotherapy.",
keywords = "adverse events, blood pressure, combination treatment, nifedipine, telmisartan",
author = "Giuseppe Derosa and Pamela Maffioli",
year = "2011",
month = "12",
doi = "10.1586/erc.11.155",
language = "English",
volume = "9",
pages = "1499--1503",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Nifedipine and telmisartan for the treatment of hypertension

T2 - The TALENT study

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

PY - 2011/12

Y1 - 2011/12

N2 - A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of atherosclerosis in hypertensive subjects and to significantly decrease cardiovascular risk in diabetic patients. Telmisartan is highly selective for the angiotensin receptor 1, it gives a greater improvement in glycemic and lipid control compared with irbesartan, and it proved its superiority in improving insulin sensitivity compared with eprosartan. The TALENT study was aimed to determine whether combining low-dose nifedipine GITS at and telmisartan reduced ambulatory and clinic blood pressure more than the two components in monotherapy in hypertensive patients at high cardiovascular risk. The study shows that combination treatment with nifedipine GITS and telmisartan provides a greater and earlier blood pressure reduction than the combination components in monotherapy.

AB - A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of atherosclerosis in hypertensive subjects and to significantly decrease cardiovascular risk in diabetic patients. Telmisartan is highly selective for the angiotensin receptor 1, it gives a greater improvement in glycemic and lipid control compared with irbesartan, and it proved its superiority in improving insulin sensitivity compared with eprosartan. The TALENT study was aimed to determine whether combining low-dose nifedipine GITS at and telmisartan reduced ambulatory and clinic blood pressure more than the two components in monotherapy in hypertensive patients at high cardiovascular risk. The study shows that combination treatment with nifedipine GITS and telmisartan provides a greater and earlier blood pressure reduction than the combination components in monotherapy.

KW - adverse events

KW - blood pressure

KW - combination treatment

KW - nifedipine

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=82755161189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755161189&partnerID=8YFLogxK

U2 - 10.1586/erc.11.155

DO - 10.1586/erc.11.155

M3 - Article

C2 - 22103868

AN - SCOPUS:82755161189

VL - 9

SP - 1499

EP - 1503

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 12

ER -